SCHEMBL6135844

SCHEMBL6135844

COC(=O)c1cc(I)c(Oc2cccc(OC)c2)c(I)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
TP53 P04637 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.48
PKM P14618 1/20 0.48
HPGD P15428 1/20 0.48
MAPK1 P28482 1/20 0.48
MTNR1B P49286 5/20 0.47
MTNR1A P48039 3/20 0.47
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
POLB P06746 2/20 0.46
PGR P06401 1/20 0.46
BLM P54132 1/20 0.46
MAPT P10636 2/20 0.45
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723673 0.87 TPMT (0.54) NPC1RAB9AMEN1KMT2AMTNR1B
SCHEMBL237992 0.86 CA1 (0.58) NPC1MEN1KMT2AALDH1A1HPGD
SCHEMBL6135987 0.86 TSHR (0.52) RAB9ASMN1; SMN2ALDH1A1HPGDPOLB
SCHEMBL358548 0.81 TPMT (0.54) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL6136142 0.80 POLB (0.44) ALDH1A1POLBMAPTLMNACA1
SCHEMBL5558318 0.80 SMN1; SMN2 (0.66) NPC1RAB9ASMN1; SMN2TP53MEN1
SCHEMBL6135981 0.79 PCNA (0.56) POLBLMNACA1CA2KDM4E
SCHEMBL6135758 0.78 KMT2A (0.44) NPC1RAB9ASMN1; SMN2TP53MEN1
SCHEMBL14024231 0.77 TPMT (0.65) ALDH1A1HPGDPOLBMAPTLMNA
Methyl 3-Methoxybenzoate SCHEMBL384913 0.76 SMN1; SMN2 (0.73) NPC1RAB9ASMN1; SMN2TP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0954299-B1 THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY FOR TREATING MALIGNANT TUMOURS OCTAMER INC (US) 2005-07-27 EP disclosed
US-6326402-B1 AROMATIC ESTER COMPOUND OCTAMER, INC. 2001-12-04 US disclosed
US-6303621-B1 ADMINISTERING DIIODO THYRONINE ANALOGUE HAVING NO SIGNIFICANT HORMONAL ACTIVITY AND A VINCA ALKALOID SELECTED FROM LEUROSINE, VINCALEUKOBLASTINE, VINBLASTINE, LEUROFORMINE, LEUROSIDINE, LEUROCRISTINE, VINCRISTINE, DEOXY VINBLASTINE OCTAMER, INC. 2001-10-16 US disclosed
EP-0954299-A4 METHOD OF TREATING MALIGNANT TUMORS WITH THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY OCTAMER INC (US) 2000-09-06 EP disclosed
WO-2000009114-A1 METHODS FOR TREATING VIRAL INFECTIONS USING A COMPOUND CAPABLE OF INHIBITING MICROTUBULES OCTAMER, INC. (US) 2000-02-24 WO disclosed
US-6017958-A A THERAPEUTIC TREATMENT USING A METHYL ALKYLOXY- OR THIO-PHENYL BENZOATE, AS POTENT, SELECTIVE AND NON-TOXIC ANTI-TUMOR AGENTS FOR TREATING CANCER OCTAMER, INC. (US) 2000-01-25 US disclosed
EP-0954299-A1 METHOD OF TREATING MALIGNANT TUMORS WITH THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY Octamer, Inc. (US) 1999-11-10 EP disclosed
US-5736576-A ADMINISTERING METHYL 3,5-DIIODO-4-(4*-METHOXYPHENOXY)BENZOATE OCTAMER, INC. (US) 1998-04-07 US disclosed
WO-1997046228-A1 METHOD OF TREATING MALIGNANT TUMORS WITH THYROXINE ANALOGUES HAVING NO SIGNIFICANT HORMONAL ACTIVITY OCTAMER, INC. (US) 1997-12-11 WO disclosed